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Abstract
Background: Details about the type of analysis (e.g., intent to treat [ITT]) and definitions (i.e., criteria for including
participants in the analysis) are necessary for interpreting a clinical trial’s findings. Our objective was to compare the
description of types of analyses and criteria for including participants in the publication (i.e., what was reported) with
descriptions in the corresponding internal company documents (i.e., what was planned and what was done). Trials were for
off-label uses of gabapentin sponsored by Pfizer and Parke-Davis, and documents were obtained through litigation.
Methods and Findings: For each trial, we compared internal company documents (protocols, statistical analysis plans, and
research reports, all unpublished), with publications. One author extracted data and another verified, with a third person
verifying discordant items and a sample of the rest. Extracted data included the number of participants randomized and
analyzed for efficacy, and types of analyses for efficacy and safety and their definitions (i.e., criteria for including participants
in each type of analysis). We identified 21 trials, 11 of which were published randomized controlled trials, and that provided
the documents needed for planned comparisons. For three trials, there was disagreement on the number of randomized
participants between the research report and publication. Seven types of efficacy analyses were described in the protocols,
statistical analysis plans, and publications, including ITT and six others. The protocol or publication described ITT using six
different definitions, resulting in frequent disagreements between the two documents (i.e., different numbers of
participants were included in the analyses).
Conclusions: Descriptions of analyses conducted did not agree between internal company documents and what was
publicly reported. Internal company documents provide extensive documentation of methods planned and used, and trial
findings, and should be publicly accessible. Reporting standards for randomized controlled trials should recommend
transparent descriptions and definitions of analyses performed and which study participants are excluded.
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Introduction
Intent to treat (ITT) analysis, which includes all participants in
the groups to which they were randomized, is typically recom-
mended as the primary type of analysis for randomized controlled
trials (RCTs) [1–3]. An ITT analysis preserves the random
assignment of participants to the study groups and thereby protects
against selection bias while estimating the treatment effect, when
no outcome data are missing. In addition to ITT, other types of
analysis (e.g., per protocol analysis) are often conducted in RCTs.
Such additional analyses, which include only a subset of all
participants in the trial, can be used to assess sensitivity of findings
compared to the primary analysis. Because each type of analysis
estimates a different parameter (i.e., population effect) and
exclusion of participants from an analysis can potentially bias its
estimate (i.e., observed effect), details on the types of analysis and
their definitions (i.e., criteria for including participants in the
analysis), and the numbers of patients randomized and analyzed
are necessary for interpreting the trial’s findings [4].
Published reports of trials, and research, in general, must be an
unbiased and accurate description of their conduct and findings
[5]. Although the Consolidated Standards of Reporting Trials
(CONSORT) statement has helped improve transparency in
reporting methods and findings from RCTs [1,3,6], it has not been
possible to identify the degree to which published reports
accurately reflect the trial conduct. One of the areas that has
not been well examined is how accurately trial publications
describe the numbers of participants randomized and how they
were analyzed. Existing research on consistency of criteria for
including participants in the analysis and transparency in
reporting focuses on two types of analysis, ITT and modified
ITT (MITT) [7–13]; this research compares either the types of
analysis across publications or what was planned in the trial
protocol with what was reported in the publication [8]. We are
unaware of research comparing what actually happened in the
trial (i.e., patients included in internal study analyses) with what
was reported in the trial publication.
Our objective was to compare, using a sample of industry-
sponsored trials, the transparency and accuracy of reporting the
numbers of participants, the description of types of analyses, and
the definitions of each type of analysis (i.e., criteria for including
participants in the analysis).
Methods
Data Sources
To achieve our study objective, we compared the description of
the types of analysis and their definitions in the internal company
protocol and research report (i.e., what was planned and what was
done) to the corresponding publication (i.e., what was reported).
The internal company documents used in our study were made
available as part of litigation against Pfizer, Inc., (the defendants),
by Kaiser Foundation Health Plan, Inc., (the plaintiffs), in Boston,
Massachusetts [14]. We conducted our study as a scholarly pursuit
independent of the litigation.
All trials included in our study were sponsored by Pfizer and
Warner-Lambert’s subsidiary Parke-Davis (Pfizer and Parke-
Davis) and related to four off-label uses of gabapentin (i.e.,
indications not approved by the US Food and Drug Administra-
tion [FDA]) [15,16]: migraine prophylaxis, and treatment of
bipolar disorders, neuropathic pain, and nociceptive pain. We
examined internal company documents and all trial publications
that were made available to one of the authors (KD) for
preparation of a report for the plaintiffs’ lawyers as part of the
litigation against Pfizer [15]. One additional trial publication was
identified through an ad hoc bibliographic search [17]. Publica-
tions for trials included in our sample were dated between 1998
and 2008 in most cases [17–26], except for one trial publication in
1987 [27]. When there was more than one publication emanating
from a trial, we specified one main publication for each trial on the
basis of the following order of priority: full-length journal article;
letter to the editor with study results; non-systematic review with
pooled analysis; conference abstract.
For each trial, we examined internal company protocols,
including amendments, and statistical analysis plans (SAPs),
research reports, and the main publications. We used the label
described in the internal company document to identify whether it
was a protocol, SAP, or a research report. Internal company
documents labeled ‘‘research report’’ were produced by or for
Pfizer and Parke-Davis and included a detailed description of the
methods, results of all statistical analyses in the trial, and a
discussion. Research reports typically also included study proto-
cols, protocol amendments, and SAPs in the appendices. We
considered internal company documents labeled ‘‘Protocol’’ as the
study protocol and those labeled ‘‘Inferential analysis plan,’’
‘‘Statistical analysis plan,’’ or ‘‘Report and analysis plan’’ as the
SAP.
We identified one main publication for 13 of 21 trials for the
four indications [17–29]. We included in our analysis 11 published
RCTs. We excluded one published trial because we did not have
access to any internal company documents [28] and another
published trial because it was not randomized and is thus, not
applicable to comparisons we made for the types of analysis [29].
In addition, we excluded eight trials that were never published.
Data Extraction and Comparisons
From the research report and the publication, we extracted data
on participant flow (i.e., number of participants assessed and
excluded for eligibility at screening, number randomized to
treatment groups, number that received and did not receive the
assigned treatment, number lost to follow-up, discontinuing
intervention, and number included in the efficacy [per the
publication-specified primary outcome] and safety analyses).
From the protocol, research report, and publication, we
extracted data on the types of analysis described for the efficacy
and safety outcomes, and the definition for each type of analysis
(i.e., criteria for including participants in the analysis).
We made the following comparisons: (1) numbers of partici-
pants randomized and analyzed for efficacy (publication-specified
primary outcome): research report versus publication (ten trials
where both documents were available). (2) types of analyses for
efficacy and safety, and their definitions: protocol versus research
report (eight trials where both documents were available); protocol
versus publication (nine trials where both documents were
available); research report versus publication (ten trials where
both documents were available).
One author (SSV) extracted data into an MS Access database
and a second author (TL) verified all of the extracted data, by
comparing it with the original documents. There was 97.5%
agreement between the two authors (SV and TL) on data
extracted from protocols and SAPs and 73% agreement on data
extracted from research reports and publications. A third author
(KD) independently verified, through reference to the original
documents, all discrepancies between the first two abstractors and
a 10% random sample of items (sample taken using a random
number table) agreed upon by the first two abstractors (complete
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agreement for the 10% sample). We resolved disagreements
among authors through discussion and consensus.
Results
Reporting on Numbers of Participants Randomized and
Analyzed: Comparing Research Reports Versus
Publications (Ten Trials Where Both Documents Were
Available)
Number randomized. There was disagreement between the
research report and the main publication on the number of
participants randomized for three of ten trials (see Table 1). For one
of the three trials, the research report described the completed study
findings while the main publication was a conference abstract
describing preliminary results [27]. We were unable to identify a
reason for the disagreement in the remaining two trials [24,26].
Number analyzed. For six of ten trials, we were unable to
compare the research report with the main publication for the
number of participants analyzed for efficacy, because the research
report either did not describe the publication-specified primary
outcome or did not describe the publication-specified type of
analysis (see Table 1 footnotes). There was agreement for four of
ten trials.
Because of substantial variations in terminology within docu-
ments related to the same trial as well as across trials, we decided
not to make comparisons between the research report and the
main publication on numbers related to participant flow. We
made this decision after two authors (SV and TL) independently
attempted to reconcile variations in terminology followed by a
consensus discussion among all authors.
Two examples of variation in terminology within documents
from the same trial follow. For study 945-220, the research report
listed 24 patients in the gabapentin group and nine in the placebo
group under the heading ‘‘Premature Discontinuation’’; and the
main publication specified that 24 patients in the gabapentin
group and nine in the placebo group were ‘‘Withdrawn’’ and
provided ‘‘Reasons for Discontinuation.’’ [23]. For study 945-276,
the research report specified that 21 patients in the gabapentin
group and ten in the placebo group ‘‘dropped out’’ but did not
provide a definition for ‘‘drop-outs’’; the main publication
described that 21 patients in the gabapentin group and nine
patients in the placebo group ‘‘Discontinued Intervention.’’ [20]
Variation in terminology may affect study findings, for example
in study 945-220, MITT was described in the publication as
follows: ‘‘This population included any patient who was random-
ized, took at least one dose of study medication during SP2
[Stabilization Period 2], maintained a stable dose of 2,400 mg/day
during SP2, had baseline migraine headache data and at least 1
day of migraine headache evaluations during SP2’’ [23].
If ‘‘Premature discontinuation’’ had meant that participants
discontinued the assigned treatment but outcomes were still
assessed during ‘‘stabilization period 2’’ of follow-up then they
would be eligible for inclusion in the MITT analysis described in
the publication.
Table 1. Total number of participants randomized and number analyzed for efficacy per research report and publication for the
publication-specified primary outcome.
Study ID Number Randomized (Total)
Number Analyzed (Total) for Publication-Specified Primary
Outcome
Research Report Publication Research Report Publication Type of Analysis
Migraine prophylaxis
879-201 [27] 87 45a Not reportedb 33a Not specified
945-220 [23] 145 145 Not reportedb 87 MITT
Bipolar disorders
945-209 [24] 118 117 114b,c 114c ITT
945-291 [26] 42 25 Not reportedb 25 ITT
Neuropathic pain
945-210 [18] 165 165 162 162 ITT
945-224 [19] 325 325 Not reportedd Not reported Not specified
945-271 [17] 120 120 98 98 ITT
945-276 [20] 121 121 Not reportedb 115 MITT
945-306 [25] 307 307 Not reportedd 305 Evaluable
945-411 [21] 339 339 339 339 ITT
No ID Gorson [22] No research reporte 40a Not availablee Not reporteda Not specified
aThe only published report available to us for study 879-201, which we used as its ‘‘main publication,’’ was a conference abstract describing preliminary results of
analyses from the trial [27]. The only published report available to us for the study, No ID Gorson, which we used as its ‘‘main publication,’’ was a letter to the editor
describing results from the trial [22]. We did not use a conference abstract, a report describing preliminary results of analyses, or a letter to the editor as the ‘‘main
publication’’ for any other trial listed in this table.
bWe could not compare the internal company research report and publication because the internal company research report did not report on the publication-specified
primary outcome.
cThe numbers presented are for Young Mania Rating Scale, which was one of two outcomes considered ‘‘primary.’’ The corresponding numbers for the other outcome
considered ‘‘primary,’’ the Hamilton Depression Rating Scale (HAM-D) are as follows: ITT: 113 in the research report and 113 in publication.
dWe could not compare the internal company document and publication because the internal company research report did not specify the type of analysis specified in
the publication, even though the outcomes were the same.
eA draft manuscript sent to Pfizer and Parke-Davis by the author reports a total of 53 patients were allocated in the trial and 40 participants were analyzed for efficacy.
doi:10.1371/journal.pmed.1001378.t001
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In contrast, if ‘‘Premature discontinuation’’ had meant that the
participants were no longer followed up for assessing outcomes
then they would not be eligible for inclusion in the MITT analysis
(in all cases where the ‘‘premature discontinuation’’ resulted in no
outcomes being assessed during stabilization period 2).
Thus, the two interpretations would mean that different subsets
of participants are included in the analysis, even while using the
same definition for the type of analysis, thereby leading to different
findings.
Reporting on the Types of Analysis for Efficacy and
Safety: Comparing Protocols Versus Research Reports
(Eight Trials Where Both Documents Were Available)
We observed extensive variability and inconsistency (i.e.,
disagreements) among documents (i.e., protocol, research report,
SAPs, and publication) within the same trial and across trials for
the types of analyses that were specified as well as their definitions.
An ITT analysis was specified in the protocol for five of eight trials
and in the research report for seven of eight trials. Both documents
described a definition for ITT in three of eight trials and there was
a disagreement in the definition for two of three trials (see Table 2).
An example of a disagreement in the definition is shown
below.
Study 945-224. The protocol defined an ITT analysis as
follows: ‘‘…this includes all patients randomized to treatment who
received at least 1 dose of study medication.’’
The methods section in the research report for the same trial
defined ITT as follows: ‘‘The ITT population was defined as all
patients randomized who received at least 1 dose of study
medication in the double-blind phase.’’
The results section in the research report defined ITT as
follows: ‘‘This population comprised all patients who received at
least 1 dose of study medication and who had an observation for
the primary efficacy parameter at baseline.’’
We also found disagreements in the definition for safety analysis
between the protocol and research report for the same eight trials.
The definition for a safety analysis was described in both
documents in the case of five of eight trials; there was disagreement
on the definition for two of five of these trials (see Table 2 and
Text S1).
Reporting on the Types of Analysis for Efficacy and
Safety: Comparing Protocols Versus Publications (Nine
Trials Where Both Documents Were Available)
Seven different types of analyses for efficacy were described in
protocols (including amendments and SAPs) and publications
across the included trials (see Table 3). The definitions for the
types of analysis were not always consistent across trials or between
the protocol and publication for the same trial.
Six different definitions for ITT were described in the protocols,
SAPs, and publications we examined (see tables 4 and 1 in Text
S1). In neither type of document did the definition for ITT ever
match its widely accepted description (i.e., all randomized patients
in the groups they were assigned) [1–3]. For three of nine trials, a
definition was available in both the protocol and publication; there
was disagreement for two of the three trials. An example of a
disagreement in the definition is shown below.
Study 945-209. The protocol defined ITT as follows: ‘‘A
secondary population will be the Intent-to-Treat population which
is defined as all patients randomized to treatment and who have at
least 1 postrandomization visit.’’
The publication defined ITT as follows: ‘‘The efficacy analyses
were carried out on the intent-to-treat (ITT) population that
included all randomized patients who received at least one dose of
study medication.’’ [24]
There were disagreements between the protocol and publica-
tion for other types of analysis for efficacy, including ‘‘modified
intent to treat (MITT),’’ ‘‘per protocol,’’ ‘‘evaluable,’’ ‘‘evaluable
for efficacy’’ and ‘‘Population to be analysed’’ (see Table 5).
Criteria for including participants in analyses of safety outcomes
were variably described in the protocols and publications across
trials. Five different definitions for the safety analysis were used in
protocols, SAPs, and publications across all included trials (see
Tables 2 and 6). For two of nine trials, the definition for safety
analysis was described in both documents and there was
disagreement on the definition in one of the two trials.
Reporting on the Types of Analysis for Efficacy and
Safety: Comparing Research Reports Versus Publications
(Ten Trials Where Both Documents Were Available)
Agreement between the research report and publication on
description of types of analysis for efficacy varied across the trials
included for this comparison. For example, while a definition for
ITT was available in both the research report and publication in
four trials there was disagreement for two of the four trials. There
was also frequent disagreement between the research report and
publication for other types of analyses for efficacy (data shown in
Text S1).
The research reports described criteria for including partici-
pants in analyses of safety more often than publications, and in
greater detail. For four of the ten trials, a definition for safety
analysis was described in both documents; there was disagreement
for one of the four trials.
Nature of Disagreements across the Trial Documents
The most commonly observed form of disagreement on types of
analyses across the documents was omission from the publication
of one or more types of analysis for efficacy specified in the trial
protocol (five of nine trials with both documents) or research
report (seven of ten trials with both documents).
Discussion
In our sample of industry-supported trials in off-label uses of
gabapentin, we observed discrepancies between what was reported
in trial publications and what was described in internal company
research reports. In this regard, we found that the trial publication
was not a transparent, or accurate (presuming that the research
report truly describes the facts), record for the numbers of
participants randomized and analyzed for efficacy. In three of ten
trials in our sample, the number of participants randomized in the
trial, as specified in the ‘‘main publication’’ [24,26,27], was not the
same as that described in the research report. The ‘‘main
publication’’ was a full-length journal article for two of the three
trials with a disagreement in the number of participants
randomized in the trial [24,26], and a conference abstract
describing preliminary results for the third trial [27]. In one case,
the description in the publication did not include data from 40%
of participants actually randomized in the trial (as described in the
research report; see Table 1) [26]. There was such wide variation
in describing the participant flow in the included trials, even
among documents for the same trial, that we were unable to
summarize what we found.
In addition, we observed extensive variability, both among
documents for the same trial and across trials, in the types of
analyses specified for efficacy and safety as well as in the criteria
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for including participants in each type of analysis; this is consistent
with Chan’s findings comparing protocols and publications [8].
Our study extends comparisons of the protocol and publication to
comparisons of analyses presented in internal company research
reports and analyses presented publicly.
We are concerned that, even for commonly used types of
analysis such as ITT, a number of different definitions were used
across trials included in our sample. Trial findings may be sensitive
to the alternative definitions used for the type of analysis, i.e.,
analyses using different definitions of the type of analysis can
include different subsets of participants, thereby leading to
different findings.
Because internal company documents are not generally
available, our study provides a unique snapshot of how well a
publication may reflect what is known by the company. Since
doctors rely on publications for information about a drug’s
effectiveness for off-label indications, our study raises particularly
important questions that may be applicable more broadly to other
drugs like gabapentin, which has been prescribed so frequently for
off-label indications [30].
Table 2. Agreement among documents from the same trial on definitions of ITT analysis and safety analysis.
Documents Compared and Criteria Assessed in Each Comparison n Published Trials
Protocol versus research report 8 total
ITT analysis
Specified in protocol 5/8
Specified in research report 7/8
Described definition in both protocol and research report 3/8
Agreement on definition of ITT between protocol and research report 1/3
Disagreement on definition of ITT between protocol and research report 2/3
Safety analysis
Specified in protocol 6/8
Specified in research report 7/8
Described definition in both protocol and research report 5/8
Agreement on definition of safety analysis between protocol and research report 3/5
Disagreement on definition of safety analysis between protocol and research report 2/5
Protocol versus publication 9 total
Definition for ITT analysis
Specified in protocol 5/9
Specified in publication 4/9
Described definition in both protocol and publication 3/9
Agreement on definition of ITT between protocol and publication 1/3
Disagreement on definition of ITT between protocol and publication 2/3
Definition for safety analysis
Specified in protocol 6/9
Specified in publication 3/9
Described definition in both protocol and publication 2/9
Agreement on definition of safety analysis between protocol and publication 1/2
Disagreement on definition of safety analysis between protocol and publication 1/2
Research report versus publication 10 total
Definition for ITT analysis
Specified in research report 9/10
Specified in publication 6/10
Described definition in both research report and publication 4/10
Agreement on definition of ITT between research report and publication 2/4
Disagreement on definition of ITT between research report and publication 2/4
Definition for safety analysis
Specified in research report 9/10
Specified in publication 4/10
Described definition in both research report and publication 4/10
Agreement on definition of safety analysis between research report and publication 3/4
Disagreement on definition of safety analysis between research report and publication 1/4
doi:10.1371/journal.pmed.1001378.t002
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Because we included a small number of trials for off-label
indications sponsored by a single company using documents
released as part of litigation, our findings may not apply to other
industry-sponsored trials, to trials for other off-label indications, or
to trials sponsored by other entities. We did not undertake a
systematic literature search to identify any additional publications
that may have described results from the included trials. In nearly
every case, since the documents associated with each trial were
obtained as part of the legal discovery process, we believe that we
have a complete list of publications for each trial.
We did not have access to the protocol for two trials and the
research report for one trial, and were unable to compare them
with the corresponding trial publication. For one trial (study 879–
201), we used a conference abstract describing preliminary results
[27] as the ‘‘main publication’’ for our comparisons with the
protocol and research report. Because the only information the
public has about the findings from study 879-201 is from the
conference abstract [27], we believe that our observations using it
are relevant in the context of our study. We are not able to
determine the cause for missing data and inadequate reporting of
data for any of the trial documents we examined. For example,
editing to meet space constraints may have been responsible for
omission of information from published reports.
In addition, we did not assess whether disagreements in
descriptions of types of analyses resulted in different participants
being analyzed for efficacy and safety. We also did not examine
the impact of the observed disagreements on the effectiveness of
gabapentin for the indications specified in our study, as meaningful
assessment would have required a systematic review of each trial
topic. We encourage this important area of research, however.
The discrepancies in description of types of analyses we
observed in our study are not unique to trials sponsored by for-
profit entities such as pharmaceutical companies. Using trial
protocols obtained from institutional review boards and corre-
sponding publications, previous research has shown that disagree-
ments such as those we described in our study can be observed in
trials with funding from both for-profit and not-for-profit entities
[8].
Our findings support recommendations that simply stating in
the publication that an analysis used ITT is not adequate [2,3].
Among the trials that reported a planned ITT analysis (about half
of the trials in our analysis) in the protocol, the definition of ITT
(i.e., which participants were included in the ITT analysis) varied.
In no case did the documents describe an ITT analysis according
to the widely accepted definition, i.e., all randomized participants
in the groups to which they were assigned. Because ITT is
recommended for the primary analysis of randomized trials [1–3],
modifying its definition, whether across studies or within a study,
defeats the purpose of a standard.
Even if the definition of an ITT is ‘‘all randomized participants
analyzed as part of the group to which they were assigned,’’ results
from a single trial can still vary depending on the method used to
impute or account for missing data (e.g., patients who missed a
visit). Indeed, a recent study showed that even among reports of
methodological studies, the definition of ITT varied with regard to
how missing outcome data are handled in the analyses [31]. A
proposed revision to the CONSORT statement reportedly will
include a requirement for describing any imputation of missing
data used to conduct an ITT analysis [32].
On the basis of our findings, we suggest that the following items
be considered for inclusion as recommended standards for
reporting trials in subsequent revisions to the CONSORT
statement: (1) explicitly state all protocol-specified type(s) of
analysis, or the analysis populations, for analyses of primary,
secondary, and safety outcomes; (2) clearly state the criteria used to
define each type of analysis, if more than one is specified; (3)
explicitly specify the numbers of participants who do not meet
each of the stated criteria, and are therefore excluded, for each
type of analysis; (4) specify terminology for consistent use across
trials, for example, for types of analysis, participants who do not
receive treatment as assigned (‘‘treatment dropouts’’), and patients
not included in the analysis (‘‘analysis dropouts’’) [4]; (5)
recommend that the individual patient data used for all analyses
described in the trial report be made accessible to the biomedical
community along with the published article.
In addition to being relevant to revisions of the CONSORT
statement, the recommendations listed above are also relevant to
the Standard Protocol Items for Randomized Trials (SPIRIT)
Initiative, which includes items on methods to handle protocol
deviations and missing data but does not explicitly require a
detailed definition for the type of analysis for efficacy and safety
[33].
Although revisions to reporting standards can contribute to
improving transparency of reporting, they cannot assure accuracy
of reporting as noted above. A variety of initiatives could improve
the situation, although there is no way to completely eliminate
deliberate fraud. Transparency, through public availability of trial
protocols, research reports, and results, is a possible solution [34].
But existing initiatives to this end do not go far enough to ensure
transparency.
Our work emphasizes that research reports, which are similar to
‘‘clinical study reports’’ described in another context [35], provide
a more comprehensive and presumably, a more accurate narrative
of the conduct of a trial and its findings than a journal publication.
For example, the research reports for trials in our sample more
often provided details about the definitions for types of analyses,
while the corresponding trial publications omitted such details.
The research reports are typically considered confidential docu-
ments and are rarely available to the public or the wider
biomedical community. Our findings lend support to the principle
that such ‘‘research reports’’ or ‘‘clinical study reports’’ must be
readily accessible to the biomedical community and the public
[35] so that the veracity of what is reported in the publications can
be assessed.
Current US legal requirements for reporting study findings are
inadequate both in scope and detail. FDA approval is not required
for off-label use of drugs. Although information on trials in off-
label uses of drugs may be submitted to the FDA, the agency’s
reviews of the trial data are made publicly available only if the
application to market the drug is approved [36–38]. Consequently,
for trials of off-label uses of drugs that are not submitted to the
FDA, or that are submitted to the FDA as part of a withdrawn or
unsuccessful application to market the drug, the only publicly
available source of information about effectiveness accessible to
most decision-makers is the published literature.
The FDA Amendments Act of 2007 requires that summary
results for trials of off-label uses of approved drugs, even some
investigational new drug-exempt trials, must be posted on
ClinicalTrials.gov, for all trials not completed before 2007
[39,40]. Having results of trials in off-label uses available publicly
allows comparison of the sponsor’s trial data with information in
publications [41–43]. It is not clear to us, however, that having
summary data available through ClinicalTrials.gov is sufficient to
allow confirmation of the trial findings by other investigators.
Certainly, the final dataset along with the full clinical study report
from industry-sponsored trials for approved drugs should be made
available by the FDA to the public for this purpose [44]. The
European Medicines Agency (EMA), in contrast, makes publicly
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accessible its summary (i.e., European Public Assessment Report)
and certain documents submitted to the agency as part of
applications requesting authorization to market drugs [35,45–47].
Other investigators have successfully obtained documents from the
EMA, including clinical study reports, to verify claims in
publications about a drug’s effectiveness [35].
Our findings highlight the need for standardizing the definitions
for various types of analyses that may be conducted to assess
intervention effects in clinical trials, delineating the circumstances
under which different types of analyses are meaningful, and
educating those who are involved in conducting and reporting
trials such that the standards are consistently adopted. We believe
that our findings lend support to policy considerations such as
extending mandatory registration to include all clinical trials
[48,49], making full trial protocols and trial data publicly available
through trial registration or other means, and ensuring that
regulations pertaining to compulsory reporting of results apply
both to trials conducted for regulatory authority-approval and to
trials in off-label indications of interventions. Health interventions
are administered to members of the public on the basis of trial
findings. It is time for the balance of power in access to
information from clinical trials to be shifted from those sponsoring
the trials to the public at large.
Supporting Information
Text S1 Additional data tables. Differences in reporting of
analyses in internal company documents versus published trial
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Editors’ Summary
Background. To be credible, published research must
present an unbiased, transparent, and accurate description
of the study methods and findings so that readers can assess
all relevant information to make informed decisions about
the impact of any conclusions. Therefore, research publica-
tions should conform to universally adopted guidelines and
checklists. Studies to establish whether a treatment is
effective, termed randomized controlled trials (RCTs), are
checked against a comprehensive set of guidelines: The
robustness of trial protocols are measured through the
Standard Protocol Items for Randomized Trials (SPIRIT), and
the Consolidated Standards of Reporting Trials (CONSORT)
statement (which was constructed and agreed by a meeting
of journal editors in 1996, and has been updated over the
years) includes a 25-point checklist that covers all of the key
points in reporting RCTs.
Why Was This Study Done? Although the CONSORT
statement has helped improve transparency in the reporting
of the methods and findings from RCTs, the statement does
not define how certain types of analyses should be
conducted and which patients should be included in the
analyses, for example, in an intention-to-treat analysis (in
which all participants are included in the data analysis of the
group to which they were assigned, whether or not they
completed the intervention given to the group). So in this
study, the researchers used internal company documents
released in the course of litigation against the pharmaceu-
tical company Pfizer regarding the drug gabapentin, to
compare between the internal and published reports the
reporting of the numbers of participants, the description of
the types of analyses, and the definitions of each type of
analysis. The reports involved studies of gabapentin used for
medical reasons not approved for marketing by the US Food
and Drug Administration, known as ‘‘off-label’’ uses.
What Did the Researchers Do and Find? The researchers
identified trials sponsored by Pfizer relating to four off-label
uses of gabapentin and examined the internal company
protocols, statistical analysis plans, research reports, and the
main publications related to each trial. The researchers then
compared the numbers of participants randomized and
analyzed for the main (primary) outcome and the type of
analysis for efficacy and safety in both the internal research
report and the trial publication. The researchers identified 21
trials, 11 of which were published RCTs that had the
associated documents necessary for comparison.
The researchers found that in three out of ten trials there
were differences in the internal research report and the main
publication regarding the number of randomized partici-
pants. Furthermore, in six out of ten trials, the researchers
were unable to compare the internal research report with
the main publication for the number of participants analyzed
for efficacy, because the research report either did not
describe the primary outcome or did not describe the type of
analysis. Overall, the researchers found that seven different
types of efficacy analyses were described in the protocols,
statistical analysis plans, and publications, including inten-
tion-to-treat analysis. However, the protocol or publication
used six different descriptions for the intention-to-treat
analysis, resulting in several important differences between
the internal and published documents about the number of
patients included in the analysis.
What Do These Findings Mean? These findings from a
sample of industry-sponsored trials on the off-label use of
gabapentin suggest that when compared to the internal
research reports, the trial publications did not always
accurately reflect what was actually done in the trial.
Therefore, the trial publication could not be considered to
be an accurate and transparent record of the numbers of
participants randomized and analyzed for efficacy. These
findings support the need for further revisions of the
CONSORT statement, such as including explicit statements
about the criteria used to define each type of analysis and
the numbers of participants excluded from each type of
analysis. Further guidance is also needed to ensure consis-
tent terminology for types of analysis. Of course, these
revisions will improve reporting only if authors and journals
adhere to them. These findings also highlight the need for all
individual patient data to be made accessible to readers of
the published article.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001378.
N For more information, see the CONSORT statement
website
N The EQUATOR Network website is a resource center for the
good reporting of health research studies and has more
information about the SPIRIT initiative and the CONSORT
statement
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